AstraZeneca has quietly delivered market-beating results since 2014. Despite skepticism, the company should be able to repeat this feat over the next 10 years.AstraZeneca (AZN -0.70%), recognized as the world's sixth-largest pharmaceutical entity by market capitalization, made a bold proclamation in May 2014. The company set an ambitious goal of achieving annual revenue exceeding $45 billion by 2023.This target was met with skepticism by Wall Street and dismissed as excessively optimistic. Contrary to these ...